

Chiara Casadei

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8362520/publications.pdf>

Version: 2024-02-01

51
papers

622
citations

687363

13
h-index

752698

20
g-index

53
all docs

53
docs citations

53
times ranked

1056
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591989028.	3.2	74
2	CAR-T cell therapy: a potential new strategy against prostate cancer. , 2019, 7, 258.		61
3	Psychosocial Issues in Long-Term Survivors of Testicular Cancer. Frontiers in Endocrinology, 2019, 10, 113.	3.5	39
4	Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110196.	3.2	36
5	Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide. Prostate Cancer and Prostatic Diseases, 2021, 24, 524-531.	3.9	32
6	The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer. Radiation Oncology, 2018, 13, 83.	2.7	23
7	<p>Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response) Tj ETQq1 1 0.7849 14 rgBT4 Overlook		
8	Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer. British Journal of Cancer, 2020, 123, 982-987.	6.4	22
9	The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment. Cancers, 2019, 11, 1935.	3.7	21
10	Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review. Critical Reviews in Oncology/Hematology, 2020, 146, 102864.	4.4	18
11	Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy. Cancers, 2021, 13, 840.	3.7	17
12	INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2). , 2021, 9, e002619.		17
13	Therapeutic Challenges for Cisplatin-Resistant Ovarian Germ Cell Tumors. Cancers, 2019, 11, 1584.	3.7	16
14	The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives. Critical Reviews in Oncology/Hematology, 2021, 157, 103199.	4.4	16
15	Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b). Frontiers in Oncology, 2021, 11, 682449.	2.8	16
16	Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors. Frontiers in Oncology, 2020, 10, 565857.	2.8	14
17	Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592096846.	3.2	14
18	Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy. Frontiers in Oncology, 2020, 10, 1325.	2.8	14

#	ARTICLE	IF	CITATIONS
19	Plasma Androgen Receptor in Prostate Cancer. <i>Cancers</i> , 2019, 11, 1719.	3.7	13
20	Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial. <i>British Journal of Cancer</i> , 2021, 125, 1226-1232.	6.4	13
21	Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 155-164.	1.9	10
22	Treatment of squamous cell carcinoma of the anal canal: A new strategies with anti-EGFR therapy and immunotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 123, 52-56.	4.4	9
23	Caregiver Emotional Burden in Testicular Cancer Patients: From Patient to Caregiver Support. <i>Frontiers in Endocrinology</i> , 2019, 10, 318.	3.5	9
24	Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2091-2099.	1.8	8
25	Human chorionic gonadotropinâ€“positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3). <i>European Journal of Cancer</i> , 2020, 132, 127-135.	2.8	8
26	<i>Aeromonas veronii</i> biovar <i>veronii</i> and sepsis-infrequent complication of biliary drainage placement: A case report. <i>World Journal of Clinical Cases</i> , 2019, 7, 759-764.	0.8	8
27	The prognostic value of pain in castration-sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 654-660.	3.9	7
28	Immunosenescence in Testicular Cancer Survivors: Potential Implications of Cancer Therapies and Psychological Distress. <i>Frontiers in Oncology</i> , 2020, 10, 564346.	2.8	7
29	Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors. <i>Journal of Oncology</i> , 2019, 2019, 1-11.	1.3	6
30	Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide. <i>Frontiers in Oncology</i> , 2020, 10, 567809.	2.8	5
31	A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103036.	4.4	5
32	Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21). <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 115-121.	2.4	5
33	Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. <i>Cancers</i> , 2022, 14, 2219.	3.7	5
34	Reclassification of good-risk seminoma: prognostic factors, novel biomarkers and implications for clinical management. <i>Future Oncology</i> , 2019, 15, 1347-1352.	2.4	4
35	The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3). <i>World Journal of Urology</i> , 2021, 39, 3407-3414.	2.2	4
36	Immune-checkpoint inhibitors and the importance of concomitant medications: focus on antibiotics. <i>Annals of Translational Medicine</i> , 2019, 7, S339-S339.	1.7	3

#	ARTICLE	IF	CITATIONS
37	Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 1950.	2.4	3
38	High-dose chemotherapy in a patient with coronavirus disease (COVID-19). <i>European Journal of Cancer</i> , 2020, 136, 130-131.	2.8	3
39	Circulating androgen receptor (AR) gene amplification and resistance to 177Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of a phase II clinical trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3020-3020.	1.6	3
40	Inflammatory Biomarkers for Outcome Prediction in Patients With Metastatic Testicular Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	3
41	Vitamin D Deficiency in Testicular Cancer Survivors: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5145.	4.1	2
42	800TiP Meet-URO 12: A randomized phase II trial of niraparib versus best supportive care (BSC) as maintenance treatment in patients with locally advanced or metastatic urothelial cancer (UC) whose disease did not progress after completion of first-line platinum-based chemotherapy. <i>Annals of Oncology</i> , 2020, 31, S607.	1.2	1
43	Germline BRCA-mutated metastatic breast cancer with positive hormone receptor. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 265-266.	2.5	1
44	Body mass index (BMI) and benefit from adjuvant chemotherapy in breast cancer: is it enough?. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 255-256.	2.5	1
45	Circulating tumor DNA fraction (ctDNA) as a surrogate predictive biomarker in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 5039-5039.	1.6	1
46	Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer. <i>Scientific Reports</i> , 2022, 12, 7319.	3.3	1
47	Immune Inflammation Indicators Predict Outcome in Anal Cancer Patients Undergoing Concurrent Chemoradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, e5-e6.	0.8	0
48	EP-1461: Immune inflammation indicators in anal cancer patients treated with concurrent chemo-radiation. <i>Radiotherapy and Oncology</i> , 2018, 127, S793-S794.	0.6	0
49	EP-1487: The prognostic role of haemoglobin in patients undergoing concurrent chemo-radiation for anal cancer. <i>Radiotherapy and Oncology</i> , 2018, 127, S806-S807.	0.6	0
50	Analysis of the androgen receptor status in liquid biopsy to predict the outcome to abiraterone and enzalutamide in CRPC patients. <i>Annals of Oncology</i> , 2019, 30, v26.	1.2	0
51	739P Impact of previous nephrectomy on clinical outcome of metastatic renal carcinoma treated with immuno-oncology: A real-world study on behalf of Meet-URO group (MeetUro-7b). <i>Annals of Oncology</i> , 2020, 31, S576.	1.2	0